4,901 trials
Acute Myeloid Leukemia · Diffuse Large B-cell Lymphoma · Acute Lymphoblastic Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
NUT Midline Carcinoma · Triple Negative Breast Cancer · Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 — 4; 2; 0; 0 Participants
GBM · Glioblastoma · Glioma
Primary: Maximum Tolerated Dose (MTD) — 10,000,000,000 50% Tissue Culture Infectious Dose
Healthy Volunteers
Primary: Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Ibuprofen. (AUC0-tz) — 140500; 139300 Hour nano gram per milliliter…
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 2405.6; 2435.5; 2422.6 μg·h/mL
Hemophilia A
Primary: Serious AEs (SAEs) and Non-serious AEs Occurring After Infusion With BAX 826 — 20; 12; 15; 0 Adverse Events
Pancreatic Cancer
Primary: Maximum Tolerated Dose — NA mg
Respiratory Syncytial Virus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) — 17; 5; 31; 30 Participants
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-935 — 477.000; 1150.889; 1882.000 nanogram per milliliter (ng/mL) — p=0.079
Healthy Subjects
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 6 participants
Hepatitis C, Chronic
Primary: Area Under the Drug Plasma Concentration-Time Curve From Start of Dosing to Time of the Last Quantifiable Sample (AUC0-last) of Uprifosbuvir — 5.34; 8.02; 3.74 µM*hr
COPD
Primary: Cmax — 53.75; 49.27; 166.79; 148.03 Pg/mL
Advanced Solid Tumours
Primary: Single Dose PK Parameter--Cmax — 6.875; 2.972 µg/mL
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0 Participants
Drug-Related Side Effects and Adverse Reactions
Primary: Mean Standardized Uptake Values (SUVs) Derived From Positron Emission Tomography-Computer Tomography (PET-CT) Data — 0.515; 0.566; 0.607; 0.623 Ratio